Millimeter-scale localization uncertainty shifted assigned biopsy doses by several Gy and made nominal DVH threshold classification frequently unreliable.
In 10 recurrent glioblastoma replans, Bragg peak proton FLASH improved conformity and reduced estimated beam delivery from approximately 17 minutes to under two seconds.
Perioperative apalutamide improved pathological response and composite MFS, but not conventional imaging-defined MFS, raising concern about overtreatment in broadly defined high-risk disease.
Extending first-generation antiandrogen therapy beyond short-term use was not associated with better survival and may increase early ADT discontinuation.
Pain should remain central for symptomatic disease, but prevention, function, local control and skeletal events require separate standardized endpoints.
Spectral hardening altered multimeter calibration by up to 11% for kerma, 37% for HVL and 42% for voltage.
Twenty-five selected patients had 96% crude local control and no grade 3 toxicity after 26 Gy in five fractions.
Twenty-year secondary uterine cancer incidence increased after pelvic radiotherapy, but absolute excess risk remained below two percentage points.
ATHENA did not improve FACT-Br scores at three months, although an exploratory nine-month analysis favoured neuropsychological integration.
Adding CTV radiomics increased internal AUROC from 0.507 to 0.754 for predicting poor response to rectal chemoradiotherapy.
Early three-dimensional CBCT shifts performed no better than chance for identifying patients with at least 3% PTV coverage loss.
Triple oHSV, radiotherapy and IGF1R blockade suppressed YAP1, produced tumour regressions and prolonged survival in glioblastoma and breast cancer models.
Five-fraction prostate radiotherapy achieved 82% three-year biochemical control with very few grade 3 toxicities in men aged 75 or older.
SBRT provided competitive peripheral coverage in some plans but could not consistently reproduce brachytherapy’s central dose escalation after realistic margins were applied.
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.